No Data
No Data
Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $70
Express News | Harmony Biosciences : BofA Global Research Cuts Price Objective to $31 From $32
Sell Rating for Harmony Biosciences Holdings Due to Patent Litigation Risks and Speculative Pipeline
Earnings Call Summary | Harmony Biosciences(HRMY.US) Q1 2025 Earnings Conference
Harmony Biosciences Projects $1B+ Opportunity for WAKIX in Narcolepsy by 2030